Spermatocele
Methodology & AI Transparency ⓘ
Spermatocele Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Prostate (BPH), Bladder & Urinary Tract practice, Spermatocele (ICD-10 N43.40) is stratified through urinalysis/urine culture [Spermatocele N43.40], pairing targeted symptom control with longitudinal IPSS Urinary Symptom in Spermatocele (N43.40: Score) surveillance.
- 2 Real-world patient consensus: Federal ICD-10-CM code N43.40 categorizes Spermatocele under Prostate (BPH), Bladder & Urinary Tract.
- 3 Typical cash cost range: Primary evaluation for Spermatocele incorporates urinalysis/urine culture [Spermatocele N43.40] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Spermatocele: maintaining Total PSA & in Spermatocele (N43.40: Serum Creatinine/eGFR) within Age-specific PSA; eGFR > 75 mL/min (N43.40).
Ask our AI Specialists anything about Spermatocele
What Is Spermatocele?
Within Prostate (BPH), Bladder & Urinary Tract practice, Spermatocele (ICD-10 N43.40) is stratified through urinalysis/urine culture [Spermatocele N43.40], pairing targeted symptom control with longitudinal IPSS Urinary Symptom in Spermatocele (N43.40: Score) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Spermatocele (code N43.40) is alpha-1A adrenergic smooth-muscle in Spermatocele (N43.40: tone narrowing the), which Prostate (BPH), Bladder & Urinary Tract clinicians address while surveilling Total PSA & in Spermatocele (N43.40: Serum Creatinine/eGFR) (Age-specific PSA; eGFR > 75 mL/min (N43.40)).
Common Symptoms & Clinical Signs
- • Presentation of Spermatocele (N43.40): weak, hesitant, or in Spermatocele (N43.40: intermittent urinary stream)
- • Secondary Spermatocele clinical sign: waking two or in Spermatocele (N43.40: more times nightly)
- • Symptom flares in Spermatocele correlating with Total PSA & in Spermatocele (N43.40: Serum Creatinine/eGFR) deviation outside Age-specific PSA; eGFR > 75 mL/min (N43.40)
- • Functional urology & prostate impact requiring urinalysis/urine culture [Spermatocele N43.40] evaluation (N43.40)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Spermatocele Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N43.40 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Total PSA & in Spermatocele (N43.40: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (N43.40) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Spermatocele (N43.40: Score) | 0 – 7 (mild symptoms) (N43.40) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Spermatocele (N43.40: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (N43.40) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Spermatocele
Treatment selection for Spermatocele depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Spermatocele)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Tadalafil administered once daily for lower urinary tract symptoms secondary to • In men with BPH-LUTS, 5 mg of tadalafil once daily during 1 year of treatment was well tolerated and efficacy changes were maintained. BJU international • 2011-04-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 21244606 ↗ |
| New Insights on Avelumab first-line maintenance for advanced urothelial carcinoma: long-term: What a 350-Participant Study Found These exploratory analyses support the efficacy and tolerability of avelumab 1L maintenance in patients aged ≥65 years with la/mUC that has not progressed following chemotherapy, suggesting that older age should not solely. ESMO open • 2025-04-15 • Phase III Randomized Trial | N = 350 | 87/100 | PMID 40107155 ↗ |
| Can This Approach Help? Inside the Latest Research on Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial Adjuvant pelvic IMRT after radical cystectomy and perioperative chemotherapy suggests an improvement in locoregional control in patients with high risk urothelial MIBC with no additional severe toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2026-07-15 • Phase III Randomized Trial | N = 153 | 82/100 | PMID 42166701 ↗ |
Spermatocele Patient Community & “People Like Me” Threads
Filter Spermatocele community threads and patient logs by age, biological sex, dosage, and treatment duration.